Anixa Biosciences Inc Total Liabilities
Anixa Biosciences Inc total liabilities. Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has total liabilities worth $1.87 Million USD as of July 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Anixa Biosciences Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Anixa Biosciences Inc (1985–2025)
Total liabilities of Anixa Biosciences Inc from 1985 to 2025. This chart illustrates how Anixa Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore ANIX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Anixa Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Anixa Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SRM CONTRACTORS ORD (BSE)
NSE:SRM
|
India | Rs2.17 Billion |
|
Pantages Capital Acquisition Corporation.
NASDAQ:PGAC
|
USA | $1.44 Million |
|
Canagold Resources Ltd
TO:CCM
|
Canada | CA$4.45 Million |
|
Silla Co.Ltd
KO:004970
|
Korea | ₩109.96 Billion |
|
Iljin Power Co. Ltd
KQ:094820
|
Korea | ₩140.38 Billion |
|
VenueG Co. Ltd
KQ:019010
|
Korea | ₩338.16 Billion |
|
e-LITECOM CO. Ltd
KQ:041520
|
Korea | ₩10.24 Billion |
|
Seer Inc
NASDAQ:SEER
|
USA | $30.96 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down Anixa Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Anixa Biosciences Inc.
Liquidity & Leverage Metrics
Anixa Biosciences Inc Total Liabilities Ratios Explained
Anixa Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anixa Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anixa Biosciences Inc (1985–2025)
The table below shows the annual total liabilities of Anixa Biosciences Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $2.13 Million | -21.20% |
| 2024-10-31 | $2.70 Million | +25.66% |
| 2023-10-31 | $2.15 Million | -2.76% |
| 2022-10-31 | $2.21 Million | +48.40% |
| 2021-10-31 | $1.49 Million | +25.41% |
| 2020-10-31 | $1.19 Million | -19.76% |
| 2019-10-31 | $1.48 Million | +17.09% |
| 2018-10-31 | $1.27 Million | +42.23% |
| 2017-10-31 | $889.49K | -80.83% |
| 2016-10-31 | $4.64 Million | +8.38% |
| 2015-10-31 | $4.28 Million | -15.14% |
| 2014-10-31 | $5.05 Million | -42.40% |
| 2013-10-31 | $8.76 Million | +27.80% |
| 2012-10-31 | $6.85 Million | -9.66% |
| 2011-10-31 | $7.59 Million | +39.22% |
| 2010-10-31 | $5.45 Million | +1.00% |
| 2009-10-31 | $5.40 Million | -6.44% |
| 2008-10-31 | $5.77 Million | +749.66% |
| 2007-10-31 | $678.81K | +16.68% |
| 2006-10-31 | $581.79K | +67.07% |
| 2005-10-31 | $348.23K | -21.41% |
| 2004-10-31 | $443.12K | +29.46% |
| 2003-10-31 | $342.29K | -17.33% |
| 2002-10-31 | $414.02K | -82.72% |
| 2001-10-31 | $2.40 Million | +79.21% |
| 2000-10-31 | $1.34 Million | -25.73% |
| 1999-10-31 | $1.80 Million | +28.57% |
| 1998-10-31 | $1.40 Million | +16.67% |
| 1997-10-31 | $1.20 Million | -36.84% |
| 1996-10-31 | $1.90 Million | +533.33% |
| 1995-10-31 | $300.00K | +50.00% |
| 1994-10-31 | $200.00K | -60.00% |
| 1993-10-31 | $500.00K | +66.67% |
| 1992-10-31 | $300.00K | +200.00% |
| 1991-10-31 | $100.00K | 0.00% |
| 1990-10-31 | $100.00K | 0.00% |
| 1989-10-31 | $100.00K | 0.00% |
| 1988-10-31 | $100.00K | 0.00% |
| 1987-10-31 | $100.00K | -50.00% |
| 1986-10-31 | $200.00K | 0.00% |
| 1985-10-31 | $200.00K | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more